An Update on PCSK9 Inhibitors

Program Goals

Support for LDL Causality in ASCVD

Genetics of LDL Lowering

Evidence For Drugs That Provide Additional LDL-C Lowering in Combination With Statins

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

Comparison of Lipid Guidelines by Society

2016 ACC Expert Consensus: Role of Non-Statin Therapies in LDL-C Lowering

2016 ESC/EAS Guidelines on the Management of Dyslipidemias: Treatment Goals for LDL-C

LDL-C: Target, Goals, and Thresholds for Non-Statin Therapy

Impact of a PCSK9 mAb on LDLR Expression

Currently Available PCSK9 Inhibitors

Lipid Research Clinics Coronary Primary Prevention Trial

Niacin: Negative Outcome Studies in Dyslipidemia

IMPROVE-IT

FOURIER: Types of Cardiovascular Outcomes

Comparison of FOURIER With Cholesterol Treatment Trialists’ Collaboration

PCSK9 Inhibitor CV Outcomes Trials

Alirocumab and Evolocumab: US Labeling and Indications

Guideline Updates on the Use of PCSK9 Inhibitors

Integrating Emerging Clinical Data Into Clinical Practice: An Evolving Treatment Algorithm

FOURIER: Safety

Safety of Low LDL-C: Alirocumab-Treated Patients in the Global Safety Pool

AACE Recommendations

Barrier Studies and Recommendations

Improving Access to PCSK9 Inhibitors

Abbreviations

Abbreviations (cont)

Abbreviations (cont)